↓ Skip to main content

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences

Overview of attention for article published in Journal of Translational Medicine, September 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (51st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
37 Mendeley
Title
The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences
Published in
Journal of Translational Medicine, September 2015
DOI 10.1186/s12967-015-0655-1
Pubmed ID
Authors

Nicola Normanno, Carmine Pinto, Francesca Castiglione, Francesca Fenizia, Massimo Barberis, Antonio Marchetti, Gabriella Fontanini, Gaetano De Rosa, Gian Luigi Taddei

Abstract

In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for the selection of metastatic colorectal cancer (mCRC) patients eligible for the therapy with anti-EGFR monoclonal antibodies. The Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytology (SIAPEC) organized an external quality assessment (EQA) scheme for CRC to evaluate inter-laboratory consistency and to ensure standardization of the results in the transition from KRAS to all-RAS testing. Ten formalin fixed paraffin embedded specimens including KRAS/NRAS (exons 2, 3, 4) and BRAF (codon 600) mutations were validated by three referral laboratories and sent to 88 participant centers. Molecular pathology sample reports were also requested to each laboratory. A board of assessors from AIOM and SIAPEC evaluated the results according to a predefined scoring system. The scheme was composed of two rounds. In the first round 36 % of the 88 participants failed, with 23 centers having at least one false positive or false negative while 9 centers did not meet the deadline. The genotyping error rate was higher when Sanger sequencing was employed for testing as compared with pyrosequencing (3 vs 1.3 %; p = 0.01; Pearson Chi Square test). In the second round, the laboratories improved their performance, with 23/32 laboratories passing the round. Overall, 79/88 participants passed the RAS EQA scheme. Standardized Human Genome Variation Society nomenclature was incorrectly used to describe the mutations identified and relevant variations were noticed in the genotype specification. The results of the Italian RAS EQA scheme indicate that the mutational analyses are performed with good quality in many Italian centers, although significant differences in the methods used were highlighted. The relatively high number of centers failing the first round underlines the fundamental role in continued education covered by EQA schemes.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 37 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 14%
Other 5 14%
Student > Bachelor 4 11%
Student > Master 4 11%
Lecturer 2 5%
Other 7 19%
Unknown 10 27%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 7 19%
Medicine and Dentistry 5 14%
Engineering 3 8%
Agricultural and Biological Sciences 2 5%
Computer Science 2 5%
Other 8 22%
Unknown 10 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 September 2015.
All research outputs
#13,446,606
of 22,826,360 outputs
Outputs from Journal of Translational Medicine
#1,586
of 3,994 outputs
Outputs of similar age
#126,114
of 266,946 outputs
Outputs of similar age from Journal of Translational Medicine
#41
of 91 outputs
Altmetric has tracked 22,826,360 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,994 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,946 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 91 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.